Keyword: Teva Pharmaceutical
All these years after its initial approval, Pfizer's little blue pill Viagra is coming to the end of its patent life.
New Teva CEO Kare Schultz is getting down to business—and quickly.
GlaxoSmithKline is pushing to grow new drug Trelegy Ellipta by seeking an expanded indication at the FDA.
Facing a rash of lawsuits claiming aggressive opioid marketing led to a nationwide epidemic, Purdue Pharma is reportedly initiating settlement talks.
AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.
Teva is reportedly looking to form a Chinese JV, Lupin was hit with an FDA warning letter, EOC Pharma raised $32 million in series B and more.
With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.
Last week, Teva's CFO said executives would be “evaluating all options” for easing the company’s debt burden. But that list of options is shrinking.
Allergan is facing allegations it betrayed shareholder interests by not disclosing details about generic price hikes.
Floundering Teva is struggling under debt pressure—but it may have a billionaire who can help with that.